Who Should And Should Not Use Semaglutide or Tirzepatide (glp-1s) #weightloss
In this concise presentation, the speaker outlines practical criteria for deciding whether to use GLP‑1 receptor agonists such as semaglutide or tirzepatide. The medication is recommended for individuals with a meaningful amount of weight to lose who also have cardiometabolic risk factors (prediabetes, type 2 diabetes, fatty liver disease, hypertension, sleep apnea) or who experience persistent preoccupation with food, binge‑eating, or ineffective results from diet therapy. Prospective users should be prepared to adopt supportive lifestyle habits—regular walking, resistance training, higher protein intake, reduced sugar, and adequate sleep—and have a realistic financial plan, as insurance coverage is not guaranteed. Contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy. The speaker emphasizes that these rare conditions warrant skipping or delaying GLP‑1 therapy.
